Gelatin tannate for acute diarrhoea and gastroenteritis in children: a systematic review and meta-analysis [documento electrónico] / Laura Fernanda Niño Serna,  . - 2020.
Obra : Archives of Disease in Childhood

Idioma : Inglés (eng)

Palabras clave :	Children  diarrhoea  gastroenteritis  gelatin  meta-analysis  systematic review  tannate
Resumen :	Objective: To determine the effectiveness and safety of gelatin tannate (GT) for reducing the duration of the acute diarrhoea and gastroenteritis (ADG) in children. Design: Systematic review and meta-analysis. Data sources: MEDLINE, Embase, CINAHL, Cochrane Central Register of Controlled Trials, LILACS and grey literature, published from inception to October 2018. No language restrictions. Eligibility criteria for selecting studies: Randomised controlled trials in children with ADG, comparing GT with placebo. Results: Of 797 titles identified, we included three studies (276 children). We performed a random effects model meta-analysis for the main outcome (diarrhoea duration). We did not find significant differences between GT and placebo for diarrhoea duration (mean difference (MD)=−15.85 hours; 95% CI −42.24 to 14.82, I2=92%; three studies), stool frequency at day 2 (MD=0.11 stools/day; 95% CI −0.39 to 0.62: I2=26%; two studies), diarrhoea at day 3 (risk ratio [RR]=0.46; 95% CI 0.06 to 3.47: I2=73%; two studies), vomiting (RR=1.31; 95% CI 0.95 to 1.80: I2=0%; two studies) or adverse events (RR=0.86; 95% CI 0.27 to 2.66: I2=0%; two studies). Most common adverse events included abdominal pain and nausea. Conclusion: The effect of GT was no different to placebo for mean diarrhoea duration (low certainty on the evidence) and stool frequency at day 2 (high certainty) and for the presence of diarrhoea at day 3 (very low certainty) of vomiting (moderate certainty) and of adverse events (low certainty).
Mención de responsabilidad :	Ivan D Florez, Javier M Sierra, Laura F Niño-Serna
Referencia :	Arch Dis Child. 2020 Feb;105(2):141-146.
DOI (Digital Object Identifier) :	10.1136/archdischild-2018-316385
PMID :	31272969
En línea :	https://adc.bmj.com/content/early/2019/07/04/archdischild-2018-316385
Enlace permanente :	https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_display&id=4241